These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 19174823)

  • 1. Prime time for a polypill after myocardial infarction?
    Fuster V
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):83. PubMed ID: 19174823
    [No Abstract]   [Full Text] [Related]  

  • 2. The polypill: An effective approach to increasing adherence and reducing cardiovascular event risk.
    Bramlage P; Sims H; Minguet J; Ferrero C
    Eur J Prev Cardiol; 2017 Feb; 24(3):297-310. PubMed ID: 27798363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A polypill strategy to improve adherence: results from the FOCUS project.
    Castellano JM; Sanz G; Peñalvo JL; Bansilal S; Fernández-Ortiz A; Alvarez L; Guzmán L; Linares JC; García F; D'Aniello F; Arnáiz JA; Varea S; Martínez F; Lorenzatti A; Imaz I; Sánchez-Gómez LM; Roncaglioni MC; Baviera M; Smith SC; Taubert K; Pocock S; Brotons C; Farkouh ME; Fuster V
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2071-82. PubMed ID: 25193393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypill opens a path for improving adherence.
    Reddy KS
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2083-5. PubMed ID: 25457397
    [No Abstract]   [Full Text] [Related]  

  • 5. Fixed-dose combination therapy and secondary cardiovascular prevention: rationale, selection of drugs and target population.
    Sanz G; Fuster V
    Nat Clin Pract Cardiovasc Med; 2009 Feb; 6(2):101-10. PubMed ID: 19104519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-benefit analysis of the polypill in the primary prevention of myocardial infarction and stroke.
    Wald NJ; Luteijn JM; Morris JK; Taylor D; Oppenheimer P
    Eur J Epidemiol; 2016 Apr; 31(4):415-26. PubMed ID: 26946426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Secondary prevention. Pills without co-pay reduce complications after myocardial infarct].
    Einecke D
    MMW Fortschr Med; 2011 Dec; 153(48):15. PubMed ID: 22299244
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of the polypill for secondary prevention in ischaemic heart disease.
    Castellano JM; Fuster V; Jennings C; Prescott E; Bueno H
    Eur J Prev Cardiol; 2017 Jun; 24(3_suppl):44-51. PubMed ID: 28618914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliminating out-of-pocket drug costs may improve outcomes after myocardial infarction--but at what cost to Medicare?
    Moran A; Goldman L
    Nat Clin Pract Cardiovasc Med; 2008 Oct; 5(10):606-7. PubMed ID: 18695697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.
    Gaziano TA; Pandya A; Sy S; Jardim TV; Ogden JM; Rodgers A; Weinstein MC
    Am Heart J; 2019 Aug; 214():77-87. PubMed ID: 31174054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cardiovascular polypill: clinical data and ongoing studies.
    Castellano JM; Bueno H; Fuster V
    Int J Cardiol; 2015 Dec; 201 Suppl 1():S8-14. PubMed ID: 26747391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health Economic Evaluation of an Ultrathin, Bioresorbable-Polymer Sirolimus-Eluting Coronary Stent Compared to a Thin, Durable-Polymer Everolimus-Eluting Stent.
    Mattke S; Hanson M; Dallmann AC; Bentele M
    Cardiovasc Revasc Med; 2019 Sep; 20(9):752-757. PubMed ID: 30638888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient preferences for a polypill for the prevention of cardiovascular diseases.
    Laba TL; Howard K; Rose J; Peiris D; Redfern J; Usherwood T; Cass A; Patel A; Jan S
    Ann Pharmacother; 2015 May; 49(5):528-39. PubMed ID: 25680761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary prevention following myocardial infarction may be improved. Long-term medication use according to practice guidelines].
    Ploegstra MJ; Kampinga MA; Croon DH; Zijlstra F; van der Horst IC
    Ned Tijdschr Geneeskd; 2010; 154():A1971. PubMed ID: 21176257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Is the "polypill" in cardiovascular prevention an option].
    Flatz A; Renard D; von Elm E
    Praxis (Bern 1994); 2015 Mar; 104(6):305-6. PubMed ID: 25758972
    [No Abstract]   [Full Text] [Related]  

  • 16. Maximizing therapeutic envelope for prevention of cardiovascular disease: role of polypill.
    Sanz G; Fuster V
    Mt Sinai J Med; 2012; 79(6):683-8. PubMed ID: 23239207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.
    González-Juanatey JR; Mostaza JM; Lobos JM; Abarca B; Llisterri JL; Baron-Esquivias G; Galve E; Lidón RM; Garcia-Moll FX; Sánchez PL; Suárez C; Millán J; Pallares V; Alemán JJ; Egocheaga I
    Med Clin (Barc); 2017 Feb; 148(3):139.e1-139.e15. PubMed ID: 27993410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the Post-MI FREEE trial: a randomized evaluation of first-dollar drug coverage for post-myocardial infarction secondary preventive therapies.
    Choudhry NK; Brennan T; Toscano M; Spettell C; Glynn RJ; Rubino M; Schneeweiss S; Brookhart AM; Fernandes J; Mathew S; Christiansen B; Antman EM; Avorn J; Shrank WH
    Am Heart J; 2008 Jul; 156(1):31-6. PubMed ID: 18585494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polypill and global cardiovascular health strategies.
    Sanz G; Fuster V
    Semin Thorac Cardiovasc Surg; 2011; 23(1):24-9. PubMed ID: 21807295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.